Evidence map›Paper›PMID 40242239›Full record

ArticleFrontiers in oncology2025

Case Report: Primary intracranial high-grade myofibroblastic sarcoma and literature review.

Xiaofeng He, Min Lv, Jin Yuan, Jun He, Xuemei Du, Yang Yang, Hong Zhang, Feng Wen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaofeng HeDepartment of Medical Oncology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, Sichuan, China.
Min LvDepartment of Medical Oncology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, Sichuan, China.
Jin YuanDepartment of Medical Oncology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, Sichuan, China.
Jun HeDepartment of Radiology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, Sichuan, China.
Xuemei DuDepartment of Pathology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, Sichuan, China.
Yang YangDepartment of Medical Oncology, The First People's Hospital of Longquanyi District, Chengdu, Chengdu, Sichuan, China.
Hong ZhangDepartment of Radiation Oncology and Department of Head & Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Feng WenAbdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade myofibroblastic sarcoma (HGMS) is exceedingly rare and highly aggressive, with a poor prognosis. Currently, there is no consensus on its definition. Wide resection is the standard of care for most patients, but clinical data on treatment outcomes remain limited. Here, we present the first reported case of HGMS originating intracranially. Surgical excision of the tumor was performed, followed by adjuvant radiotherapy with a total dose of 60 Gy in 30 fractions. As of November 2024, the patient had achieved 24 months of recurrence-free survival. This case may provide new evidence that could be useful for the treatment of rare primary intracranial HGMS.

Indexed as

case reporthigh-grade myofibroblastic sarcomaprimary intracranialradiotherapyresection

Identifiers

PMID40242239
PMCPMC12000069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.